Pentraxin-3 is known to promote the transition of monocytes to fibrocytes, though little is known about its role in myelofibrosis.
Primary myelofibrosis (PMF), a rare myeloproliferative neoplasm, involves enlarged spleen, hematopoiesis occurring in organs outside of the bone marrow, and progressive bone marrow (BM) fibrosis. The level of BM fibrosis is known to correlate with poor survival.
Writing in a letter to The British Journal of Haematology, a research team explained that, in seeking to identify the mechanism of BM fibrosis, they identified large numbers of fibrocytes in the BM, as well as increased levels of the pentraxin C-reactive protein (CRP) in the plasma, of patients with PMF. Another pentraxin, pentraxin-3 (PTX3), is known to promote the transition of monocytes to fibrocytes, though little is known about PTX3’s role in PMF.
The team examined PTX3 plasma levels from 140 patients with PMD and compared them with 30 samples from healthy volunteers, and found that PTX3’s plasma levels were significantly higher in patients with PMF, as were CRP plasma levels. They also found that high CRP levels were associated with unfavorable overall survival (OS).
Read more about treating myelofibrosis.
Using a multivariate Cox proportional hazard regression model, the researchers found that OS was independently predicted by both PTX3 (HR, 1.77, P = .03) and CRP (HR, 1.95, P = .019). Furthermore, high PTX3 and high CRP correlated with unfavorable prognostic indicators identified in the Dynamic International Prognostic Scoring System’s risk stratification.
Furthermore, PTX3 levels were also correlated with parameters of tumor burden, including total leucocyte count and spleen size, and with the severity of patients’ constitutional symptoms and performance status.
“Our data suggest that PTX3 plasma levels constitute an independent indicator of disease burden, clonal expansion and overall survival in patients with PMF,” concluded the authors. “Therefore, monitoring of PTX3 plasma levels might be a useful tool in clinical decision making.”
Reference
Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumor burden and overall survival in patients with primary myelofibrosis. [Published online August 3, 2018.] Br J Haematol. doi: 10.1111/bjh.15528.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen